Kailera Therapeutics, Inc. quarterly report, Q3 FY2026

Kailera Therapeutics, Inc. — Form 10-Q summary

Reporting period: Quarter and nine months ended September 30, 2026; filed November 4, 2026. Kailera is a clinical-stage biotechnology company developing obesity therapies and has not generated revenue.

Financial results and position

MetricQ3 2026Q3 2025Nine months 2026Nine months 2025
Revenue$0$0$0$0
Research and development expense$84.7m$27.0m$256.6m$56.6m
General and administrative expense$21.7m$13.1m$55.8m$34.6m
Total operating expenses$106.3m$40.1m$312.4m$91.2m
Net loss$95.7m$39.6m$285.8m$86.6m
Interest income$10.6m$2.3m$26.3m$6.1m
  • Cash and investments: $1,037.6m at September 30, 2026, including $106.5m cash and cash equivalents and $931.1m marketable securities. Cash, cash equivalents and restricted cash totaled $107.3m.
  • Balance sheet: Total assets were $1,082.2m; total liabilities $51.1m; stockholders’ equity $1,031.1m; accumulated deficit $654.5m.
  • Debt and liquidity: The filing reports no outstanding borrowings at quarter-end. Operating lease liabilities were $10.0m, with undiscounted lease payments of $14.1m. The company says cash and investments should fund operations into mid-2028 in MD&A; the financial-statement note separately says funding is sufficient for at least twelve months from issuance.
  • Cash flows, nine months: $279.5m used in operations, $437.3m used in investing, and $663.1m provided by financing. Financing primarily reflects the IPO.
  • Margins: Not applicable as the company had no revenue. No product revenue or profitability guidance was provided.

Material changes and business developments

  • Net loss increased by $56.0m in Q3 and $199.3m for the first nine months versus the comparable 2025 periods, chiefly as clinical and development spending expanded. R&D spending was driven principally by ribupatide injection, including $175.1m for the nine-month period.
  • On April 20, 2026, Kailera completed its IPO, selling 44.9m shares at $16 per share and receiving $662.0m net proceeds. Existing preferred shares converted into 84.6m common shares. The company reported 129.7m shares outstanding at September 30 and 129.9m as of October 29.
  • Management describes four clinical-stage candidates: Phase 3 ribupatide injection; oral ribupatide; oral GLP-1 candidate safiglipron; and injectable KAI-4729. The company’s claim that ribupatide injection may offer the greatest weight loss is a company belief, not established by head-to-head trials.
  • The filing’s “Recent developments” section reports completion of enrollment in the ribupatide injection global Phase 3 program, with data anticipated mid-2028. It also describes expected oral ribupatide Phase 3 initiation in the first half of 2027, safiglipron Phase 2 data anticipated mid-2027, and a KAI-4729 Phase 1 trial targeted by year-end 2026.

Outlook, risks and contingencies

  • Management expects significant operating losses and rising R&D expense as trials advance; there is no committed external funding source. Additional financing may dilute shareholders, constrain operations, or require licensing rights to others.
  • Key risks include clinical-trial efficacy, safety, enrollment and timing; FDA or foreign regulatory disagreement; manufacturing capacity and quality; reliance on Hengrui and acceptance of China-generated data; and intense competition in obesity treatments.
  • The Hengrui license includes up to $200m in clinical and regulatory milestones, up to $5.7bn in commercial milestones, and tiered royalties. These contingent payments are not included in the contractual-obligations table.
  • Ribupatide injection trials have observed drug-related nausea, vomiting, diarrhea and alopecia. No material legal proceedings were reported. Management stated disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
  • Marketable securities had $3.7m in aggregate unrealized losses at September 30. Management attributed declines primarily to market conditions, stated it did not intend or expect to need to sell before recovery, and recorded no credit-loss allowance.

Important facts for investors to verify

  • Reconcile the cash-runway statements: “at least twelve months” in the notes versus “into mid-2028” in MD&A, including the underlying spending and trial assumptions.
  • Check the chronology of the “Recent developments” disclosures: the filing is signed November 4, 2026, yet describes announcements dated November 2026.
  • Track actual Phase 3 enrollment completion, data timing, oral ribupatide regulatory alignment, and planned safiglipron and KAI-4729 milestones.
  • Assess quarterly cash burn, investment maturities, equity-award dilution, and financing needs against the stated runway.
  • Monitor Hengrui dependence, manufacturing arrangements, China-related trade and regulatory risks, and the scope and timing of contingent milestone and royalty obligations.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.